Rasna Therapeutics, Inc. filed its 10-K on Feb 09, 2023 for the period ending Sep 30, 2022. In this report its auditor, Marcum LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.011 USD | -12.00% | -36.42% | +42.86% |
1st Jan change | Capi. | |
---|---|---|
+42.86% | 8.49M | |
+5.21% | 109B | |
+11.32% | 105B | |
-0.38% | 22.25B | |
-12.01% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.90% | 16.85B | |
+3.23% | 13.76B | |
+36.51% | 12.46B |
- Stock Market
- Equities
- RASP Stock
- News Actavia Life Sciences, Inc.
- Rasna Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt